CN1192688A - 联合疗法治疗hiv和其它病毒性感染 - Google Patents

联合疗法治疗hiv和其它病毒性感染 Download PDF

Info

Publication number
CN1192688A
CN1192688A CN96196051A CN96196051A CN1192688A CN 1192688 A CN1192688 A CN 1192688A CN 96196051 A CN96196051 A CN 96196051A CN 96196051 A CN96196051 A CN 96196051A CN 1192688 A CN1192688 A CN 1192688A
Authority
CN
China
Prior art keywords
hiv
peptide
effective dose
pharmaceutically acceptable
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96196051A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·约翰森
D·M·兰伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trimeris Inc
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of CN1192688A publication Critical patent/CN1192688A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN96196051A 1995-06-07 1996-06-06 联合疗法治疗hiv和其它病毒性感染 Pending CN1192688A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48195795A 1995-06-07 1995-06-07
US08/481,957 1995-06-07

Publications (1)

Publication Number Publication Date
CN1192688A true CN1192688A (zh) 1998-09-09

Family

ID=23914065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96196051A Pending CN1192688A (zh) 1995-06-07 1996-06-06 联合疗法治疗hiv和其它病毒性感染

Country Status (10)

Country Link
US (2) US6475491B1 (enExample)
EP (1) EP0831873A4 (enExample)
JP (1) JPH11507632A (enExample)
KR (1) KR100571215B1 (enExample)
CN (1) CN1192688A (enExample)
AU (1) AU723537B2 (enExample)
BR (1) BR9609152A (enExample)
CA (1) CA2224008C (enExample)
NZ (1) NZ311319A (enExample)
WO (1) WO1996040191A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127300A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽、其药物组合物及其用途

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
WO2000066622A1 (en) 1999-05-05 2000-11-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7053179B2 (en) 1999-12-16 2006-05-30 Whitehead Institute For Biomedical Research Five-Helix protein
AU2001233340B2 (en) 2000-02-10 2006-05-04 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
EP1267919A2 (en) * 2000-03-17 2003-01-02 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
MXPA03011453A (es) 2001-06-15 2004-04-05 Hoffmann La Roche Acetilacion de fragmentos de gp41.
US7094413B2 (en) * 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
EP1542718B1 (en) 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
AP2005003294A0 (en) * 2002-09-27 2005-06-30 Tanox Inc Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
DE602004031390D1 (de) * 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
CA2522690A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050281829A1 (en) * 2003-05-06 2005-12-22 Hehir Cristina A T Fc chimeric proteins with anti-HIV drugs
US20080096809A1 (en) * 2003-12-22 2008-04-24 Yeda Research & Development Co. Ltd. Diastereomeric Peptides Useful as Inhibitors of Membrane Protein Assembly
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
WO2005118886A2 (en) 2004-06-01 2005-12-15 Merck & Co., Inc. Stable peptide mimetic of hiv gp41 fusion intermediate
US20060154895A1 (en) * 2004-12-09 2006-07-13 Maxwell Gordon Method of treating acquired immunedeficiency syndrome
GB0501352D0 (en) * 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
DK1989220T3 (da) 2006-02-02 2012-04-02 Trimeris Inc HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008019817A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
CA2673085C (en) 2006-12-12 2013-10-15 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
JP2010523564A (ja) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP2616487B1 (en) 2010-09-14 2015-03-25 F.Hoffmann-La Roche Ag Serpin-finger fusion polypeptide
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
JP2019524687A (ja) 2016-07-01 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗体薬物複合体およびこれを用いた治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
GB8815241D0 (en) 1988-06-27 1988-08-03 Wellcome Found Antiviral combinations & compounds therefor
ATE135113T1 (de) 1988-12-20 1996-03-15 Clarity Technologies Inc Synthetische hiv ähnliche peptide, deren zusammensetzungen und verwendungen
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
WO1994002505A1 (en) * 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127300A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽、其药物组合物及其用途
CN103974971A (zh) * 2012-02-28 2014-08-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽、其药物组合物及其用途
CN103974971B (zh) * 2012-02-28 2016-09-14 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽、其药物组合物及其用途

Also Published As

Publication number Publication date
CA2224008C (en) 2009-08-18
KR19990022685A (ko) 1999-03-25
MX9709682A (es) 1998-06-30
US6861059B2 (en) 2005-03-01
CA2224008A1 (en) 1996-12-19
JPH11507632A (ja) 1999-07-06
BR9609152A (pt) 1999-05-04
US6475491B1 (en) 2002-11-05
US20030103998A1 (en) 2003-06-05
AU6261996A (en) 1996-12-30
EP0831873A1 (en) 1998-04-01
EP0831873A4 (en) 2002-07-17
KR100571215B1 (ko) 2006-10-24
WO1996040191A1 (en) 1996-12-19
NZ311319A (en) 2000-01-28
AU723537B2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
CN1192688A (zh) 联合疗法治疗hiv和其它病毒性感染
US5464933A (en) Synthetic peptide inhibitors of HIV transmission
CN1205995C (zh) 具有增强药物动力特性的杂合肽
Morrison et al. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones.
CN1254271C (zh) 增强了药动学性质的杂合多肽
RU2174845C2 (ru) Композиции и способы доставки генетического материала
Baldwin et al. Inhibiting HIV-1 entry with fusion inhibitors
SK287382B6 (sk) Očkovacia kompozícia
CN1377275A (zh) 抑制病毒感染的肽及其使用方法
JP2021175746A (ja) 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
Dedera et al. Role of asparagine-linked glycosylation in human immunodeficiency virus type 1 transmembrane envelope function
CN1321165A (zh) 病毒性疾病的预防和治疗
CN1100564C (zh) 用于治疗hiv感染的药物、其组合物及其用途
CN1309970A (zh) 尿苷磷酸化酶抑制剂的制药应用及含其的组合物
CN1668330A (zh) Hiv感染的肽衍生物融合抑制剂
CN1207775A (zh) 条件复制型病毒载体及其用法
CN1929860A (zh) HIV gp41衍生肽的位点特异性化学修饰
CN1481251A (zh) 治疗病毒感染的联合方法
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗
CN1612942A (zh) 病毒衣壳组装中间产物
CN1793170A (zh) 抑制hiv病毒融合的多肽及其用途
SARVER et al. Frontiers in HIV-1 therapy: Fourth conference of the NIAID national cooperative drug discovery groups-HIV
Wright et al. Treatment of chronic viral hepatitis
MXPA97009682A (en) The treatment of hiv infections and other viral infections using a combined therapy
Alkhatib et al. eee iS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication